Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases

What is the effect of finerenone in patients with chronic kidney disease due to glomerular diseases?In this prespecified exploratory analysis of a randomized clinical trial that enrolled 903 participants with glomerular diseases, finerenone, compared with placebo, slowed kidney function decline (difference in eGFR slope decline, 073 mL/min/1.73 m per year), reduced albuminuria, and lowered the risk of kidney failure or sustained loss of kidney function, with consistent effects across glomerular disease subtypes.Finerenone may have an important role in preserving kidney function in patients with glomerular diseases.

Corresponding Author: Brendon L. Neuen, MBBS, MSc, PhD, The George Institute for Global Health, Health Translation Hub, Level 8, 55 Botany Rd, Randwick NSW 2031, Australia (bneuen@georgeinstitute.org.au).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.